Skip to main content

Advertisement

SpringerLink
Log in

Resistant hypertension and the birmingham hypertension square

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Recent guidelines for the treatment of hypertension place great emphasis on tighter blood pressure control, especially in the presence of hypertensive target organ damage and diabetes. In order to achieve these treatment targets, more patients will require a combination of antihypertensive medications. However, resistant hypertension may have many possible underlying causes, and clinicians should appreciate how to detect and tackle these potential problems. Effective and synergistic combinations are therefore of vital importance, especially in patients with resistant hypertension. The choice of rational first- and second-line drugs that act in synergy could lead to better blood pressure management as well as significant financial savings for health care resources. The use of the Birmingham Hypertension Square for the optimum choice of add-in drugs for the treatment of resistant hypertension may aid management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446.

  2. Cornoni-Huntley J, LaCroix AZ, Havlik RJ: Race and sex differentials in the impact of hypertension in the United States. Arch Intern Med 1989, 149:780–788.

    Article  PubMed  CAS  Google Scholar 

  3. Shaper AG, Ashby D, Pocock SJ: Blood pressure and hypertension in middle-aged British men. J Hypertens 1988, 6:367–374.

    PubMed  CAS  Google Scholar 

  4. Collins R, Peto R, MacMahon S: Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised trials in their epidemiological context. Lancet 1990, 335:827–838.

    Article  PubMed  CAS  Google Scholar 

  5. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999, 17:151–183. These guidelines for the management of hypertension provide excellent information on the following: 1) hypertension as a cardiovascular risk factor, 2) interventions to reduce that risk, 3) patient evaluation, 4) treatment recommendations, and 5) difficult to manage patient groups.

    Google Scholar 

  6. Avanzini F, Alli C, Bettelli G, et al.: Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. Eur Heart J 1994, 15:206–212.

    PubMed  CAS  Google Scholar 

  7. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug therapy in the person with isolated systolic hypertension. JAMA 1991, 265:3255–3264.

    Article  Google Scholar 

  8. MRC Working Party: MRC trial of mild hypertension. Br Med J 1985, 291:97–104.

    Google Scholar 

  9. Burt VL, Cutler JA, Higgins M, et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995, 26:60–69.

    PubMed  CAS  Google Scholar 

  10. Yakovlevitch M, Black HR: Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786–1792.

    Article  PubMed  CAS  Google Scholar 

  11. Klein LE: Compliance and blood pressure control. Hypertension 1988, 2(suppl II):II61-II64.

    Google Scholar 

  12. Danielson M, Dammstrom B: The prevalence of secondary and curable hypertension. Acta Med Scand 1981, 209:451–455.

    Article  PubMed  CAS  Google Scholar 

  13. Rudnick KV, Sackett DL, Hirst S, Holmes C: Hypertension in a family practice. Can Med Assoc J 1977, 117:492–497.

    PubMed  CAS  Google Scholar 

  14. Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976, 2:554–556.

    PubMed  CAS  Google Scholar 

  15. Wilhelmsen L, Berglund G: Prevalence of primary and secondary hypertension. Am Heart J 1977, 94:543–546.

    Article  PubMed  CAS  Google Scholar 

  16. Brown MJ, Haydock S: Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000, 59(suppl 2):1–12. Cardiovascular risk can be determined by target organ damage, other medical conditions associated with increased risk, and lifestyle factors such as obesity and smoking. After the nonpharmacologic approach, selection of initial drug therapy should be based on the strength of evidence for reduction of cardiovascular mortality in controlled clinical trials, and should also take into account coexisting medical conditions that favor or limit the usefulness of any given drug.

    Article  PubMed  Google Scholar 

  17. Waeber B, Scherrer U, Petrillo A, et al.: Are some hypertensive patients overtreated? A prospective study of ambulatory blood pressure recording. Lancet 1987, 2:732–744.

    Article  PubMed  CAS  Google Scholar 

  18. Mejia AD, Egan BM, Schork NJ, Zweifler AL: Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment resistant hypertension. Ann Intern Med 1990, 112:270–277.

    PubMed  CAS  Google Scholar 

  19. Schotte DE, Stunkard AJ: The effect of weight reduction on blood pressure in 301 obese patients. Arch Intern Med 1990, 150:1701–1704.

    Article  PubMed  CAS  Google Scholar 

  20. Puddey IB, Beilin LJ, Vandongen R: Regular alcohol use raises blood pressure in treated hypertensive subjects: a randomised controlled trial. Lancet 1987, 1:647–651.

    Article  PubMed  CAS  Google Scholar 

  21. Groppelli A, Giorgi DM, Omboni S, et al.: Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992, 10:495–499.

    Article  PubMed  CAS  Google Scholar 

  22. Messerli FH, Ventura HO, Amodeo C: Osler’s maneuver and pseudohypertension. N Engl J Med 1985, 312:1548–1551.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.

    PubMed  CAS  Google Scholar 

  24. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328:914–921.

    Article  PubMed  CAS  Google Scholar 

  25. Clark LT: Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991, 121(2 Pt 2):664–669.

    Article  PubMed  CAS  Google Scholar 

  26. Nussberger J, Waeber B, Brunner HR: Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition. Am J Hypertens 1989, 2:286–293.

    PubMed  CAS  Google Scholar 

  27. Radevski I, Skudicky D, Candy G, et al.: Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens 1999, 12(2 Pt 1):194–203.

    Article  PubMed  CAS  Google Scholar 

  28. Hall WD: Pathophysiology of hypertension in blacks. Am J Hypertens 1990, 3(12 Pt 2):366S-371S.

    PubMed  CAS  Google Scholar 

  29. Dickerson JE, Hingorani AD, Ashby MJ, et al.: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353:2008–2013. A crossover rotation of the four main classes of antihypertensive drugs in untreated hypertensive patients assessed the response rate with monotherapy. Four monthly cycles of treatment with an ACE inhibitor (A), b-blocker (B), calcium channel blocker (C), and diuretic (D) was assessed. Optimization of treatment requires systematic rotation can be abbreviated if initially one of each of the two pairs of treatments "AB/CD" is selected.

    Article  PubMed  CAS  Google Scholar 

  30. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757–764.

    Article  PubMed  CAS  Google Scholar 

  31. Hanson L, Zanchetti A, Carruthers SG, et al.: HOT Study Group.Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762. The HOT Study showed that lowering the diastolic blood pressure down to 82.6 mm Hg is associated with a low rate of cardiovascular events. Acetylsalicylic acid significantly reduced major cardiovascular events with the greatest benefit seen in all myocardial infarction, but nonfatal major bleeds were twice as common.

    Article  Google Scholar 

  32. Nifedipine-Atenolol Study Review Committee: Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Br Med J (Clin Res Ed) 1988, 296:468–472.

    Google Scholar 

  33. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985, 291:97–104.

    Google Scholar 

  34. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255–3264.

    Article  Google Scholar 

  35. Frishman WH, Bryzinski BS, Coulson LR, et al.: A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994, 154:1461–1468.

    Article  PubMed  CAS  Google Scholar 

  36. Soffer BA, Wright JT, Jr, Pratt JH, et al.: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995, 26:112–117.

    PubMed  CAS  Google Scholar 

  37. Zezulka AV, Gill JS, Dews I, et al.: Comparison of enalapril and bendrofluazide for treatment of systemic hypertension. Am J Cardiol 1987, 59:630–633.

    Article  PubMed  CAS  Google Scholar 

  38. Brouwer RM, Bolli P, Erne P, et al.: Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985, 7(suppl 1):S88-S91.

    PubMed  Google Scholar 

  39. Singer DR, Markandu ND, Cappuccio FP, MacGregor GA:Studies of captopril alone and in combination with the benzothiazepine, diltiazem or the dihydropyridine nifedipine in treating essential hypertension. J Cardiovasc Pharmacol 1991, 18(suppl 9):S51-S54.

    Google Scholar 

  40. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA:Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. J Cardiovasc Pharmacol 1985, 7(suppl 1):S82-S87.

    PubMed  Google Scholar 

  41. MacGregor GA, Cappuccio FP: Lack of effect of a diuretic added to diltiazem. J Hum Hypertens 1997, 11:249–250.

    PubMed  CAS  Google Scholar 

  42. Zezulka AV, Gill JS, Beevers DG: The effects of bendroflumethiazide added to nifedipine in patients with hypertension. J Clin Pharmacol 1987, 27:41–45.

    PubMed  CAS  Google Scholar 

  43. Graves JW, Bloomfield RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989, 298:361–365.

    Article  PubMed  CAS  Google Scholar 

  44. Cappucino FP, Makanuda ND, Whithcer F, MacGregor GA:Doxazosin in combination therapy for resistant hypertension. J Hypertens 1994, 12(suppl 3):S108.

    Google Scholar 

  45. Forslund T, Fyhrquist F, Hortling L: Sustained antihypertensive effect of captopril combined with diuretics and beta-adrenergic blocking drugs in patients with resistant hypertension. Acta Med Scand 1983, 213:299–303.

    Article  PubMed  CAS  Google Scholar 

  46. Ramsey LE, Parnell L, Walker PC: Comparison of nifedipine, prazosin, and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker. Postgrad Med J 1987, 63:99–103.

    Google Scholar 

  47. Potter JF, Beevers DG: Comparison of nifedipine and captopril as third-line agents in hypertensive patients uncontrolled with beta-blocker and diuretic therapy. J Clin Pharmacol 1987, 27:410–404.

    PubMed  CAS  Google Scholar 

  48. Bevan EG, Pringle SD, Walker PC, et al.: Comparison of captopril, hydralazine, and nifedipine as third drug in hypertensive patients. J Hum Hypertens 1993, 7:83–88.

    PubMed  CAS  Google Scholar 

  49. McAreavey D, Ramsy LE, Latham L, et al.: "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta-blocker plus thiazide diuretic. BMJ 1984, 288:106–111.

    PubMed  CAS  Google Scholar 

  50. Lip GYH, Beevers M, Beevers DG: The ‘Birmingham Hypertension Square’ for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens 1998, 12:761–763. An easy to use aid for effective antihypertensive combination therapy in resistant hypertension is offered.

    Article  PubMed  CAS  Google Scholar 

  51. Nalbantgil I, Onder R, Kiliccioglu B, Turkoglu C: Combination therapy with verapamil and nitrendipine in patients with hypertension. J Hum Hypertens 1993, 7:305–308.

    PubMed  CAS  Google Scholar 

  52. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967–1975.

    Article  Google Scholar 

  53. Marshall HJ, Beevers DG: b-Adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility. Br J Clin Pharmacol 1996, 42:507–509.

    Article  PubMed  CAS  Google Scholar 

  54. Beevers DG, Hamilton M, Fairman MJ, Harpur JE: The influence of antihypertensive treatment over the incidence of cerebral vascular disease. Postgrad Med J 1973, 49:905–907.

    Article  PubMed  CAS  Google Scholar 

  55. Isles CG, Walker LM, Beevers GD, et al.: Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986, 4:141–156.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City Hospital, University Department of Medicine, B18 7QH, Birmingham, UK

    Dirk C. Felmeden MD, MRCP & Gregory Y. H. Lip MD, FACC

Authors
  1. Dirk C. Felmeden MD, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y. H. Lip MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Felmeden, D.C., Lip, G.Y.H. Resistant hypertension and the birmingham hypertension square. Current Science Inc 3, 203–208 (2001). https://doi.org/10.1007/s11906-001-0039-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-001-0039-1

Keywords

Search

Navigation